Denali Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2026 to a ratio of 3.2, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the third quarter 2026. Average receivable collection period, for the Denali Therapeutics Inc in Sep 30 2026 quarter, has decreased to 114 days, compared to 198 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector Denali Therapeutics Inc achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Denali Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DNLI Receivables Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Receivable Change	-	-	-	-	-
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	3.2	1.84	-	-	-
DNLI's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	114	199	-	-	-
Seq. Receivable Change	380.83 %	0 %	-	-	-
Seq. Revenue Change	393.29 %	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

DNLI Company Profile • Back to DNLI Efficiency Comparisons • Compare DNLI Receivables Turnover Ratio to its Competitors

Financial Statements
Denali Therapeutics Inc 's Accounts Receivable	$ 19 Millions	Visit DNLI's Balance sheet
Denali Therapeutics Inc 's Sales TTM	$ 21 Millions	Visit DNLI's Income Statement
Sources of DNLI's Revenues		Visit DNLI's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DNLI's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DNLI's Growth Rates	DNLI's Roa	DNLI's Inventory Turnover Ratio	DNLI's Dividend Comparisons
DNLI's Profitability Ratios	DNLI's Roi	DNLI's Asset Turnover Ratio	DNLI's Dividend Growth
DNLI's Valuation Ratios	DNLI's Roe	DNLI's Financial Strength Ratios	DNLI's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2026	Receivable at quarter ending Sep 30 2026
Phathom Pharmaceuticals Inc	3.02	$ 274.881 Millions	$ 90.969 Millions
Regeneron Pharmaceuticals Inc	2.64	$ 16,896.200 Millions	$ 6,404.025 Millions
Amarin Corp Plcuk	1.50	$ 176.609 Millions	$ 118.128 Millions

Date modified: 2026-11-04T16:54:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.